Ceapro Inc V.CZO

Alternate Symbol(s): CRPOF

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc

<< Previous

Bullboard Posts

Next >>

Post by lscfaon Apr 29, 2024 10:45am

78 Views

Post# 36012586

Revenue by geography

	US	Germany	China	Other	Canada	Total
Q4 23	1,067,406	577,326	0	1,756	4,370	1,650,858
Q3 23	1,703,035	893,466	1,533	13,331	7,608	2,618,973
Q2 23	1,048,761	690,909	2,296	113,900	12,892	1,868,758
Q1 23	785,821	2,645,763	6,874	48,874	7,479	3,494,811
Q4 22	1,456,152	1,404,374	402,429	40,917	18,342	3,322,214
Q3 22	1,585,084	1,812,292	432,229	7,645	8,120	3,845,370
Q2 22	3,837,675	1,132,572	514,327	11,125	4,700	5,500,399
Q1 22	4,192,890	1,585,756	375,524	10,464	6,990	6,171,624
Q4 21	1,673,884	624,945	1,231,852	11,252	20,042	3,561,975
Q3 21	2,835,586	1,479,502	187,432	12,975	7,485	4,522,980
Q2 21	3,442,902	860,186	60,452	20,134	24,957	4,408,631
Q1 21	3,437,280	1,037,319	191,290	18,783	17,071	4,701,743
Q4 20	1,657,173	814,713	200,835	13,708	19,883	2,706,312
Q3 20	3,180,388	190,680	82,665	14,122	7,770	3,475,625
Q2 20	2,034,647	1,623,775	974,744	11,132	21,673	4,665,971
Q1 20	3,530,946	660,425	40,862	26,384	14,757	4,273,374
Q4 19	2,377,247	725,394	591,733	9,361	17,634	3,721,369
Q3 19	1,923,574	445,499	521,102	9,034	8,771	2,907,980
Q2 19	1,640,732	779,518	602,111	21,832	9,534	3,053,727
Q1 19	2,072,821	727,097	361,410	28,846	6,756	3,196,930
Q4 18	3,844,772	454,546	149,016	8,540	10,375	4,467,249
Q3 18	1,456,751	548,363	83,294	30,139	5,915	2,124,462
Q2 18	1,362,080	817,466	500,717	43,062	8,050	2,731,375
Q1 18	1,636,777	451,328	115,939	60,633	4,903	2,269,580
Q4 17	2,370,693	562,821	14,744	15,040	5,550	2,968,848
Q3 17	3,380,216	183,552	18,815	9,527	8,132	3,600,242
Q2 17	2,152,365	559,862	433,837	27,161		3,173,225
Q1 17	2,473,426	678,908	12,430	18,746		3,183,510
Q4 16	1,836,186	433,744	120,916	28,675	5,331	2,424,852
Q3 16	2,207,465	776,073		25,013	9,128	3,017,679
Q2 16	2,319,232	1,620,378	147,295	68,718	12,232	4,167,855
Q1 16	2,198,382	1,718,010	88,953	45,574	12,657	4,063,576
Q4 15	1,251,618	1,636,913	516,724	26,086	3,091	3,434,432
Q3 15	2,126,291	917,576		33,063	2,229	3,079,159
Q2 15	1,493,146	837,585	80,332	28,303		2,439,366
Q1 15	1,281,148	408,087		23,943	1,307	1,714,485